A scientific meeting that I would have liked to have attended and one where I think attendees will obtain a lot of insight into the future of prostate cancer research is the forthcoming American Association for Cancer Research (AACR) Advances in Prostate Cancer Research meeting.
Chaired by Charles Sawyers (MSKCC) and Arul Chinnayan (Michigan) it has an impressive line-up of speakers and sessions. The meeting takes place next week (Feb 6-9) in Orlando.
There are two presentations on cabozantib (XL184) that may offer new insights into the mechanism of action of the drug and its potential:
Cabozantinib (XL-184) and prostate cancer: Preclinical and clinical profile of a novel agent
Maha Hussain, University of Michigan Medical School, Ann Arbor, MI
Cabozantinib (XL184) inhibits androgen-sensitive and castration-resistant prostate cancer in the bone and increases bone formation in non-tumored bones Eva Corey, University of Washington, Seattle, WA
A few of the presentations at the meeting that caught my attention include:
- Role of inflammation (William Nelson)
- Influence of tumor microenvironment on progression and resistance (Christopher Logothetis),
- Novel therapeutic targets in prostate cancer (Arul Chinnaiyan)
- Overcoming castration-resistant prostate cancer (Charles Sawyers)
If you have in an interest in prostate cancer research, February 6-9 in Orlando is the place to be.